Total Payments
$113,842
2021 Payments
$8,741
Companies
2
Transactions
21
Payment Breakdown by Category
Research$113,842 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $113,842 | 21 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Endo Pharmaceuticals Inc. | $106,939 | 20 | $0 (2021) |
| Allergan Inc. | $6,903 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $8,741 | 2 | Endo Pharmaceuticals Inc. ($8,741) |
| 2019 | $96,499 | 10 | Endo Pharmaceuticals Inc. ($96,499) |
| 2018 | $1,699 | 8 | Endo Pharmaceuticals Inc. ($1,699) |
| 2017 | $6,903 | 1 | Allergan Inc. ($6,903) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/14/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $3,123.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 08/17/2021 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,618.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 11/12/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,986.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 10/15/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,918.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 09/10/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $15,707.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 08/06/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,597.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 07/09/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $4,300.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 06/18/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $14,918.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 05/14/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,423.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 04/16/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,930.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 03/19/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $8,895.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 02/19/2019 | Endo Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $14,825.00 | Research |
| Study: A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | ||||||
| 02/11/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $812.99 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/11/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $302.33 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/11/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $178.36 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/11/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $51.98 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/10/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $120.88 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/10/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $64.73 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/10/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $51.28 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 02/09/2018 | Endo Pharmaceuticals Inc. | — | — | In-kind items and services | $116.88 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | ||||||
| 12/31/2017 | Allergan Inc. | — | — | Cash or cash equivalent | $6,902.52 | Research |
| Study: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN MALES WITH A COMPARATOR ARM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3B, OPEN-LABEL, LONG-TERM STUDY TO EVALUATE THE SAFETY AND TEMPORAL PATTERN OF RESPONSE OF EN3835 IN THE TREATMENT OF EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | Endo Pharmaceuticals Inc. | $105,240 | 12 |
| MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A STUDY OF SETIPIPRANT TABLETS IN ANDROGENETIC ALOPECIA IN MALES WITH A COMPARATOR ARM | Allergan Inc. | $6,903 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $1,699 | 8 |
About Dr. Gary Petrus, MD
Dr. Gary Petrus, MD is a Plastic Surgery Within the Head and Neck healthcare provider based in N Little Rock, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568525806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Petrus, MD has received a total of $113,842 in payments from pharmaceutical and medical device companies, with $8,741 received in 2021. These payments were reported across 21 transactions from 2 companies. The most common payment nature is "" ($113,842).
Ad
Practice Information
- Specialty Plastic Surgery Within the Head and Neck
- Other Specialties Plastic and Reconstructive Surgery
- Location N Little Rock, AR
- Active Since 12/18/2006
- Last Updated 01/25/2019
- Taxonomy Code 2082S0099X
- Entity Type Individual
- NPI Number 1568525806
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.